Skip to main content
SpringerLink
Log in

Antiasthmatics/guaifenesin/nivolumab

Nasal polyposis, eosinophillic asthma and lack of efficacy :case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rembalski S, et al. Nivolumab-associated Nasal Polyposis and Eosinophilic Asthma Responsive to Benralizumab, An Anti-IL5R Biologic. Journal of Immunotherapy 45: 370-373, No. 8, Oct 2022. Available from: URL: http://doi.org/10.1097/CJI.0000000000000430

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antiasthmatics/guaifenesin/nivolumab. Reactions Weekly 1926, 44 (2022). https://doi.org/10.1007/s40278-022-24322-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-24322-2

Search

Navigation